Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Cancer Research

• Publication date

  2002-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 12006521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

  2001cited by this paper
• Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

  1999influential reference
• Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.

  1999cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

  1998cited by this paper
• Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

  1996cited by this paper
• Hazard rate estimation under random censoring with varying kernels and bandwidths.

  1994cited by this paper
• Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

  1993cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

  1992cited by this paper
• Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women

  1992cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Nanoparticle Albumin-Bound-Paclitaxel Instead of Standard Paclitaxel in Adjuvant Chemotherapy Regimen for Breast Cancer Under COVID-19 Pandemic—A Single Center Feasibility Study in China

  2022cites this paper
• Chemotherapy in pregnancy

  2022cites this paper
• The Antiproliferative and Pro-apoptotic Role of 2-aminoethyl dihydrogen Phosphate in Triple-negative Breast Tumor Cells

  2021cites this paper
• Preoperative treatment of HER2-positive breast cancer

  2020cites this paper
• Adjuvant Systemic Chemotherapy for HER2-Negative Disease

  2019cites this paper
• Taxanes for adjuvant treatment of early breast cancer.

  2019cites this paper
• Phase 2 Study of Dose‐Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate With or Without Prophylactic Growth Factor for Adjuvant Treatment of Early‐Stage Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

  2018cites this paper
• TAXANES IN ADJUVANT BREAST CANCER TREATMENT

  2018cites this paper
• Adjuvant Chemotherapy for HER2-Negative Early-Stage Breast Cancer

  2018cites this paper
• Does the Timing of Chemotherapy Affect Post‐Mastectomy Breast Reconstruction Complications?

  2017cites this paper
• 1 Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

  2017cites this paper
• Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study

  2017cites this paper
• Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?

  2017cites this paper
• Which is More Effective; Docetaxel, Doxorubicin and Cyclophosphamide Or 5-Fluorouracil, Doxorubicin and Cyclophosphamide in Adjuvant Treatment of Early Stage Node Positive Breast Cancer?

  2017cites this paper
• Phase II study of neoadjuvant anthracycline combined with nanoparticle albumin-bound paclitaxel for human epidermal growth factor receptor 2-negative breast cancer.

  2017cites this paper
• Febrile Neutropenia Risk with Adjuvant Docetaxel and Cyclophosphamide (TC) Chemotherapy Regimen in Two Brazilians Cancer Centers

  2017cites this paper
• Comparison of Surgical Complications Between Immediate Breast Reconstruction and Mastectomy: The Impact on Delivery of Chemotherapy

  2016cites this paper
• Chapitre 10 – Principes des chimiothérapies adjuvantes et néoadjuvantes des cancers du sein localisés

  2016cites this paper
• Efficacy and safety of doublet versus single agent as salvage treatment for metastatic breast cancer pretreated with anthracyclines and taxanes: a systematic review and meta-analysis

  2016cites this paper
• Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

  2016cites this paper
• Adjuvant chemotherapy in early breast cancer.

  2016cites this paper
• Indication of metronomic chemotherapy for metastatic breast cancer: Clinical outcomes and responsive subtypes.

  2016cites this paper
• Continued value of adjuvant anthracyclines as treatment for early breast cancer.

  2015cites this paper
• Is chemotherapy dose intensity adequate in breast cancer management in the Australian healthcare setting: A retrospective analysis

  2014cites this paper
• Factors responsible for long-term survival in metastatic breast cancer

  2014cites this paper
• BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling

  2014cites this paper
• Clinical pharmacology during pregnancy

  2013cites this paper
• Place des taxanes en adjuvant dans le traitement des cancers du sein sans envahissement ganglionnaire

  2013cites this paper
• [Impact of taxanes in the adjuvant setting of node-negative breast cancers].

  2013cites this paper
• 14 – Chemotherapy in Pregnancy

  2013cites this paper
• If there is no overall survival benefit in metastatic breast cancer: does it imply lack of efficacy? Taxanes as an example.

  2013cites this paper
• Breast Cancer Patients' Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy

  2013cites this paper
• Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

  2013cites this paper
• The safety and tolerability of FE 100 C-D chemotherapy in a non-trial population of node positive breast cancer compared to PACS-01 trial group; Salmaniya Medical Complex experience

  2013cites this paper
• Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.

  2013cites this paper
• Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.

  2013cites this paper
• A Comparison of Surgical Complications Between Immediate Breast Reconstruction and Mastectomy: The Impact on Delivery of Chemotherapy—An Analysis of 391 Procedures

  2012cites this paper
• Epithelial Cell Dissemination and Readhesion: Analysis of Factors Contributing to Metastasis Formation in Breast Cancer

  2012cites this paper
• CMF revisited in the 21st century.

  2012cites this paper
• Taxanes in the adjuvant treatment of node-negative breast cancer patients.

  2012cites this paper
• Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis

  2012cites this paper
• Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

  2012cites this paper
• Adjuvant Taxanes in Breast Cancer: A Critical Re-appraisal

  2011cites this paper
• Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group.

  2011cites this paper
• Adjuvant Chemotherapy, with or without Taxanes, in Early or Operable Breast Cancer: A Meta-Analysis of 19 Randomized Trials with 30698 Patients

  2011cites this paper
• Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.

  2011cites this paper
• TAXTOX – a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009

  2011cites this paper
• Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial

  2011cites this paper
• Controversies in the management of adjuvant breast cancer with taxanes: review of the current literature.

  2011cites this paper
• Review on cancer and anticancerous properties of some medicinal plants

  2011cites this paper
• Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer

  2011cites this paper
• Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control

  2011cites this paper
• Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials

  2011cites this paper
• Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients

  2011cites this paper
• Chemotherapy for breast cancer (Review).

  2010cites this paper
• Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer

  2010cites this paper
• Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

  2010cites this paper
• Adjuvant Systemic Therapy for Breast Cancer: An Overview

  2010cites this paper
• Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

  2010cites this paper
• Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel.

  2009cites this paper
• Overview of Major Classes of Plant-Derived Anticancer Drugs

  2009cites this paper
• Role of anthracyclines in the treatment of early breast cancer.

  2009cites this paper
• Combining systemic therapies with radiation in breast cancer.

  2009cites this paper
• Taxanes in the Adjuvant Treatment of Early Breast Cancer, Emerging Consensus and Unanswered Questions

  2009cites this paper
• Drug Therapy for Breast Cancer

  2009cites this paper
• Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer

  2009cites this paper
• The use of paclitaxel in the management of early stage breast cancer.

  2009cites this paper
• Richtlijn behandeling van het mammacarcinoom

  2008influential citation
• Estudio transversal del tratamiento del cáncer de mama en España

  2008cites this paper
• 01 Farmacia May-Jun.QXD

  2008cites this paper
• Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.

  2008cites this paper
• Progress in the Treatment of Early and Advanced Breast Cancer

  2008cites this paper
• Estudio transversal del tratamiento del cáncer de mama en España Grupo Español para

  2008cites this paper
• Docetaxel in adjuvant therapy of breast cancer : results of the TAXIT 216 multicenter phase III trial ”

  2008cites this paper
• Taxanes, microtubules and chemoresistant breast cancer.

  2008influential citation
• [Transversal study of breast cancer treatment in Spain].

  2008cites this paper
• Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

  2008cites this paper
• Combining chemotherapy with radiation in breast cancer

  2008cites this paper
• Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study

  2008cites this paper
• Estudio transversal del tratamiento del cáncer de mama en España

  2008cites this paper
• Nowe możliwości w uzupełniającym leczeniu systemowym chorych na raka piersi

  2007cites this paper
• Actualización del tratamiento adyuvante en cáncer de mama

  2007cites this paper
• Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

  2007cites this paper
• Les taxanes sont-ils toujours indispensables?

  2007cites this paper
• Taxanes for adjuvant treatment of early breast cancer.

  2007cites this paper
• Traitement adjuvant du cancer du sein n’exprimant pas HER2

  2007cites this paper
• Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.

  2007cites this paper
• Adjuvant systemic therapy for operable breast cancer.

  2007cites this paper
• Breast Cancer: A Review of Risk Factors, Screening and Treatment

  2006cites this paper
• Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient

  2006cites this paper
• Taxane-containing chemotherapy in the treatment of early breast cancer patients.

  2006cites this paper
• Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

  2006cites this paper
• Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.

  2006cites this paper
• Benefit of taxanes as adjuvant chemotherapy for early breast cancer

  2006cites this paper
• Cancers du Sein Métastatique

  2006cites this paper
• Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants

  2006cites this paper
• Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions

  2006cites this paper
• Taxane Therapy for Early Stage Breast Cancer

  2006cites this paper
• Chemotherapy--overview and future perspectives.

  2006cites this paper
• Adjuvant Chemotherapy in Primary Breast Cancer

  2006cites this paper